NasdaqCM - Nasdaq Real Time Price USD

Ocugen, Inc. (OCGN)

0.7093

+0.0147

+(2.12%)

At close: May 15 at 4:00:00 PM EDT

0.7000

-0.01

(-1.31%)

Pre-Market: 8:34:28 AM EDT

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ...

Ocugen Inc (OCGN) outlines ambitious plans for gene therapy advancements while navigating increased expenses and cash flow concerns.

GuruFocus.com 6 days ago

OCGN
+2.12%
Ocugen: Q1 Earnings Snapshot

MALVERN, Pa. AP) — Ocugen, Inc. OCGN) on Friday reported a loss of $15.4 million in its first quarter.

Associated Press Finance 7 days ago

OCGN
+2.12%
Ocugen Provides Business Update with First Quarter 2025 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2

GlobeNewswire 7 days ago

OCGN
+2.12%
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call usin

GlobeNewswire 14 days ago

OCGN
+2.12%
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of ge

GlobeNewswire 17 days ago

OCGN
+2.12%
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look at where Ocugen Inc. (NASDAQ:OCGN) stands against other penny stocks to invest in under $1. Earlier on February 12 this year, Chief Investment Officer at Cetera Financial Group, Gene […]

Insider Monkey 29 days ago

OCGN
+2.12%
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy. “I look forward to sharing more on how Ocugen’s modifier gene therapy platform can pot

GlobeNewswire last month

OCGN
+2.12%
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks last month

OCGN
+2.12%
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

The open-label trial aims to evaluate the drug's safety when administered via intravitreal injection.

Clinical Trials Arena last month

OCGN
+2.12%
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data follo

GlobeNewswire last month

OCGN
+2.12%
Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY...

Simply Wall St. 2 months ago

OCGN
+2.12%
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market competition.

GuruFocus.com 2 months ago

OCGN
+2.12%
Q4 2024 Ocugen Inc Earnings Call

Q4 2024 Ocugen Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

OCGN
+2.12%
Ocugen (OCGN) Q4 2024 Earnings Call Transcript

OCGN earnings call for the period ending December 31, 2024.

Motley Fool 2 months ago

OCGN
+2.12%
Ocugen: Q4 Earnings Snapshot

MALVERN, Pa. AP) — Ocugen, Inc. OCGN) on Wednesday reported a loss of $13.9 million in its fourth quarter.

Associated Press Finance 2 months ago

OCGN
+2.12%
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable

GlobeNewswire 2 months ago

OCGN
+2.12%
Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

Ocugen (OCGN) said Monday that the European Medicines Agency's Committee for Advanced Therapies issu

PREMIUM
MT Newswires 2 months ago

OCGN
+2.12%
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) for OCU410 and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being develope

GlobeNewswire 2 months ago

OCGN
+2.12%
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission. The GARDian trial for OCU410ST demonstrated: A favorab

GlobeNewswire 2 months ago

OCGN
+2.12%
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings an

GlobeNewswire 2 months ago

OCGN
+2.12%

Performance Overview

Return	OCGN	S&P 500 (^GSPC)
YTD	-11.89%	+0.60%
1-Year	-63.81%	+11.47%
3-Year	-66.22%	+47.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocugen, Inc. (OCGN)

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ...

Ocugen: Q1 Earnings Snapshot

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

Q4 2024 Ocugen Inc Earnings Call

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

Ocugen: Q4 Earnings Snapshot

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Performance Overview